RPRX
Royalty Pharma Plc
58.30$
+1.1%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +34.7% | -14.0% | -1.0% | +6.9% | +5.5% | -19.7% | -38.9% | +93.0% | +17.7% | -8.1% | -9.8% | – | |
| – | – | – | – | -200.0% | – | – | – | -7.4% | -6.3% | -2.1% | -200.0% | – | |
| – | +6.2% | -0.8% | +11.3% | -22.8% | -0.2% | -1.9% | +17,525.0% | -19.8% | +72.7% | -3.0% | -12.2% | – | |
| – | – | -161.6% | – | -137.4% | – | -225.1% | – | -202.4% | – | +1,621.7% | -300.0% | – | |
| – | +122.2% | -91.4% | +767.3% | +11.5% | -100.0% | – | – | – | -100.0% | – | – | – | |
| – | +121.9% | -91.3% | +930.8% | +33.5% | -57.6% | – | -161.9% | +207.2% | -11.5% | -38.6% | -64.0% | – | |
| – | -0.5% | +5.0% | +1.2% | -0.9% | -0.4% | +1.8% | -2.2% | +2.2% | -1.0% | +10.8% | +0.4% | – | |
| – | -78.4% | -100.0% | – | +21.3% | -45.8% | +1,247.3% | -58.9% | -49.8% | -45.0% | -37.8% | -10.9% | – | |
| – | – | – | – | – | – | – | – | – | -100.0% | – | – | – | |
| – | -82.9% | -8.6% | – | -128.1% | -20.7% | +264.9% | -46.1% | – | -153.2% | -9.0% | +0.2% | – | |
| – | – | – | +151.8% | -188.4% | – | – | -387.2% | – | -204.3% | – | – | – | |
| – | +34.7% | -14.0% | -1.0% | +6.9% | +5.5% | -19.7% | -38.9% | +93.0% | +17.7% | -8.1% | -9.8% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.